What Rainwater Charitable Foundation does

The Rainwater Charitable Foundation (RCF) is a private family foundation based in Fort Worth, Texas, established in 1991 by private-equity investor Richard E. Rainwater and operating as a 501(c)(3) nonprofit under Texas law. RCF is a grant-making entity, not a commercial enterprise: it deploys capital from its endowment across three program areas — Family Economic Security (K-12 education, upskilling, affordable housing, childcare for North Texas families), Medical Research (focused on primary tauopathies such as PSP, CBD, Pick's disease, and FTD), and Other Foundation Programs (scholarships, East Africa education, EdTech, cultural access). Since 2012 it has deployed over $426M in total, split across Family Economic Security ($240.3M+), Medical Research ($166.7M+), and Other Foundation Funding ($103.9M+), and has supported 500+ organizations globally. The organization runs on 11-50 employees.

RCF's medical research work is its most sophisticated and structured area, built around the Tau Consortium (a collaborative research and drug-discovery network), the Rainwater Prize program (awards from $200K up to a $10M Breakthrough Prize for PSP treatments), the Tauopathy Challenge Workshop (grants up to $500K over two years), and the Sprint-to-Lead drug discovery grants (up to $400K). It underwrites shared research infrastructure — including one of the world's largest tauopathy brain banks (11,000+ samples at Mayo Clinic Florida), a Bioinformatics Hub, and a Human iPSC line collection — and coordinates biorepository access through partners such as ALLFTD, NCRAD, and BioSEND. The foundation reports 8 treatments advanced into human trials through its support. The medical thesis treats primary tauopathies as "pathfinder diseases" whose insights may transfer to more common conditions like Alzheimer's.

RCF has no conventional revenue model; it does not sell products or generally accept individual donations, funding activity instead through its endowment and program-related investments (e.g., an EQ2 investment in CDFI Capital Good Fund and gap financing for the Maren Grove affordable-housing project). Grants are distributed via competitive, invitation-only, and LOI-based processes managed through a Grantee Portal, and the foundation extends its reach through co-funding partnerships with the Alzheimer's Association, CurePSP, Aging Mind Foundation, Michael J. Fox Foundation, and FNIH. Leadership includes President Jeremy Smith, EVP/CFO Melissa Parrish, and CIO Aaron Bigbee. Following the May 2026 death of long-serving trustee Walter Rainwater, RCF is in a transition period during which the Letter of Inquiry process has been temporarily paused pending a recalibration of funding priorities.

Name

Rainwater Charitable Foundation

Legal name

Rainwater Charitable Foundation

Website

https://rainwatercharitablefoundation.org

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Rainwater Charitable Foundation is a Fort Worth-based private family foundation, founded 1991, making grants across North Texas family economic security, primary-tauopathy medical research, and education programs, having deployed over $426M to 500+ organizations globally.

Ownership category

akta.pro rank

Product category

Philanthropic Foundation

NAICS

Grantmaking Foundations (813211), Voluntary Health Organizations (813212)

SIC

Services-Social Services (8300)

akta.pro primary industry

Community Foundations (BPAGAKAB)

akta.pro secondary industries

Health & Medical Research Grantmaking Foundations (BPAGAKAL), Education Grantmaking Foundations (BPAGAKAK)

Keywords

• Philanthropic grantmaking
• Neurodegenerative research funding
• Tauopathy research grants
• Family foundation giving
• Community education grants

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others, Personnel, Operations

Distribution channels4 records

Marketing channels9 records

Core offering

The Rainwater Charitable Foundation is a private family foundation that makes grants across three program areas: Medical Research (funding tauopathy and neurodegenerative disease research through the Tau Consortium, Rainwater Prize, Tauopathy Challenge Workshop, and Sprint to Lead Drug Discovery grants); Family Economic Security (supporting North Texas families through quality education, upskilling, affordable housing, and childcare); and Other Foundation Programs (Africa education initiatives and scholarships). It also operates program-related investments and a Grantee Portal for grant management.

Product overview

The Rainwater Charitable Foundation (RCF) is a private family foundation with three primary program areas: Family Economic Security, Medical Research, and Other Foundation Programs. The Medical Research Program is the most technology-focused, comprising the Tau Consortium (collaborative research network), the Rainwater Prize (award program), the Tauopathy Challenge Workshop (funding initiative), and the Sprint to Lead Drug Discovery Grant. RCF also provides research infrastructure including the Tau Consortium Bioinformatics Hub and Human iPSC Line Collection for the scientific community. The Foundation does not operate as a unified software platform but rather as a collection of grant-making programs and research resources.

Differentiator

Problem solved

Functional benefit

Brands

• Tau Consortium: A collaborative research program managed and funded by RCF that commissions world-class research and drug discovery programs to treat and prevent primary tauopathies.
• Rainwater Prize
• Tauopathy Challenge Workshop
• Sprint to Lead (S2L)

Products and services

• Tau Consortium Collaborative research program funded and managed by RCF that commissions world-class research and drug discovery programs to treat and prevent primary tauopathies. It fosters high-impact networks of scientists to better understand tauopathies and guide development of effective treatments.
• Rainwater Prize Award program recognizing scientific progress toward new treatments for neurodegenerative diseases associated with tau protein accumulation. Includes Outstanding Innovation in Neurodegenerative Research ($400K), Innovative Early-Career Scientists ($200K), Milestone Prize for Advances in Tauopathy Research (up to $2M), and Breakthrough Prize for Effective Treatments in PSP ($2M-$10M).
• Tauopathy Challenge Workshop A funding program established in 2023 that convenes interdisciplinary experts around a single topic to address unmet needs in primary tauopathies. Provides up to $500,000 in direct costs over two years for research grants, with up to four awards funded annually.
• Sprint to Lead (S2L) Drug Discovery Grant Program Grant program inviting original ideas focused exclusively on accelerating the development of therapies for primary tauopathies within the hit-to-lead and lead optimization development phases of drug discovery. Awards up to $400,000 direct costs for one year.
• Tau Consortium Bioinformatics Hub Centralized platform providing researchers with high-quality computational tools, curated multi-omics datasets, analytical pipelines, and bioinformatics training resources to advance the study of tau biology and neurodegenerative disease.
• Tau Consortium Human iPSC Line Collection A rigorously characterized repository of induced pluripotent stem cell (iPSC) lines derived from donors with tauopathy-linked mutations as well as matched controls, hosted via the Neural Stem Cell Institute.
• Family Economic Security Program RCF program committed to supporting North Texas families and children through quality education, upskilling, affordable housing, and childcare. Includes Early Childhood & Family Support, K-12 Education, Upskilling, and Community Asset Building funding areas.
• Grantee Portal Online portal for grant recipients to manage their grants and reporting.
• DASH Pass Program A card that provides free access to museums, theaters, and cultural institutions across Fort Worth for families, aiming to reduce barriers to enriching experiences for children.

Quantifiable outcome

• 8 treatments advanced into human trials through RCF medical research support
• +6 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

19 partnerships are on record, tiered core and minor.

• Aging Mind FoundationcoreStrategic or Co-development Partner · 13 August 2025Co-funding partner for the Tauopathy Challenge Workshop, contributing to $2.5 million in grants for five neurodegenerative disease research projects in 2025. The partnership aims to support novel, mechanism-focused research for primary tauopathies.
• Alzheimer's AssociationcoreStrategic or Co-development Partner · 13 August 2025Collaborative partner in the Tauopathy Challenge Workshop, co-funding grants for neurodegenerative disease research. Also partner in The Tau Pipeline Enabling Program (T-PEP). Host of Tau Global Conference with RCF.
• CurePSPcoreStrategic or Co-development Partner · 13 August 2025Co-funding partner for the Tauopathy Challenge Workshop and multiple joint initiatives including the Biomarker Accelerator Program, Pathway and Pipeline Grant Program, Prime of Life Brain Initiative, and PSP Genetics Consortium. Co-host of Tau Global Conference.
• Foundation for the National Institutes of Health (FNIH)coreStrategic or Co-development PartnerPartner in the Biomarkers Consortium for Neurofilament as a Blood-Based Biomarker of Neurodegeneration in FTD.
• The Association for Frontotemporal Degeneration (AFTD)coreStrategic or Co-development PartnerPartner in the FTD Diagnostic Biomarkers Initiative to advance diagnostic capabilities for frontotemporal degenerations.
• FTD Disorders RegistryminorStrategic or Co-development PartnerRegistry connecting patients with clinical trials and research studies for FTD and related conditions.
• Bluefield ProjectminorStrategic or Co-development PartnerPartner in the Neurofilament Light Surveillance Project (NSP) for neurodegenerative disease research.
• Michael J. Fox FoundationcoreStrategic or Co-development PartnerPartner in Philanthropic Investments in PET Tracers (PIPETTE) for 4R tau and alpha-synuclein PET tracer development.
• Health Resources in Action (HRiA)minorStrategic or Co-development PartnerPartnered with RCF to map the biorepository landscape for primary tauopathies, developing a searchable database and identifying bottlenecks in sample access.
• Mayo Clinic FloridacoreStrategic or Co-development PartnerHome to one of the world's largest tauopathy brain banks (11,000+ samples) led by Rainwater Prize winners Drs. Dickson and Murray. Key research partner in tauopathy neuropathology.
• O-SDA IndustriesminorStrategic or Co-development PartnerDevelopment partner for the 90-unit Maren Grove affordable housing property in South Fort Worth, where RCF provided gap financing through subordinate, concessionary debt.
• ALLFTD (ARTFL LEFFTDS Longitudinal FTLD)coreStrategic or Co-development PartnerRCF provides access to ALLFTD biospecimens and data through its tauopathy resources page, including genomic DNA, RNA, plasma, serum, PBMCs and CSF samples.
• NCRAD (National Centralized Repository for Alzheimer’s Disease & Related Dementias)coreStrategic or Co-development PartnerRCF provides access to NCRAD biospecimens and coordinates for researchers through its primary tauopathy resources page.
• BioSEND (Biospecimen Exchange for Neurological Disorders)coreStrategic or Co-development PartnerRCF directs researchers to BioSEND for broader neurodegenerative disease cohorts including primary tauopathies and non-tauopathies.
• Neural Stem Cell InstitutecoreStrategic or Co-development PartnerHosts the Tau Consortium Human iPSC Line Collection providing patient-derived stem cell lines for tauopathy research.
• NIH NeuroBioBankminorStrategic or Co-development PartnerRCF references NIH NeuroBioBank as an example of coordinated biorepository infrastructure for post-mortem brain tissue access.
• LISC (Local Initiatives Support Corporation)minorStrategic or Co-development PartnerCommunity development financial institution that RCF mentions as potential PRI partner for managed funds focusing on affordable housing and small business capital.
• University of BaselcoreStrategic or Co-development PartnerHome institution of 2026 Rainwater Prize winner Dr. Marc Aurel Busche, conducting research on soluble tau species and neuronal dysfunction.
• UK Dementia Research Institute at University College LondoncoreStrategic or Co-development PartnerAffiliated institution of 2026 Rainwater Prize winner Dr. Marc Aurel Busche, supporting research on tau-related dementia mechanisms.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Alzheimer's Association: Largest nonprofit funder of Alzheimer's disease research and a core RCF partner in the Tauopathy Challenge Workshop and Tau Global Conference. Both organizations fund neurodegenerative research and engage with overlapping scientific and patient communities.
• Doris Duke Charitable Foundation: Large private family foundation with significant medical research funding alongside arts, environment, and child welfare programs. Structurally similar as a multi-program family foundation with comparable scale and grantmaking approach.
• Howard Hughes Medical Institute: Major biomedical research organization funding investigator-initiated research through HHMI investigators. Comparable as a substantial private medical research funder with research infrastructure investments and scientific talent development.

Direct peers

• CurePSP: Nonprofit focused specifically on PSP, CBD, and other prime of life neurodegenerative diseases, co-funding multiple RCF initiatives including the Biomarker Accelerator Program and PSP Genetics Consortium. Most direct peer given overlapping focus on primary tauopathies.
• Michael J. Fox Foundation: Leading nonprofit funder of Parkinson's disease research with an analogous venture philanthropy model, including milestone-driven grants and PET tracer development. RCF partner in the PIPETTE initiative for tau and alpha-synuclein tracers.
• Bluefield Project: Nonprofit focused on FTD research, partnering with RCF on the Neurofilament Light Surveillance Project. Direct peer given shared focus on frontotemporal degeneration and tau-related disease research.
• BrightFocus Foundation: Nonprofit that funds research on Alzheimer's, macular degeneration, and glaucoma through grants to investigators. Comparable grantmaking model and neurodegenerative disease focus with similar scale and approach to research funding.
• ALS Association: Major nonprofit funder of amyotrophic lateral sclerosis research, with a similar venture philanthropy model including drug discovery funding and clinical trial support. Comparable approach to accelerating neurodegenerative disease treatments.

Emerging players

• Hereditary Disease Foundation: Family-founded nonprofit focused on Huntington's disease and other hereditary neurodegenerative disorders. Comparable in scale, founding model (family foundation), and focus on rare neurological disease research.
• Target ALS: Nonprofit focused on accelerating ALS drug development through collaborative funding models. Comparable venture philanthropy approach with milestone-driven grants and research consortia, though focused on a different neurodegenerative disease.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/RCFNeuro
• LinkedInlinkedin.com/company/rainwater-charitable-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rainwater Charitable Foundation